Originally published July 18, 2008 at 12:00 AM | Page modified July 19, 2008 at 11:18 AM

Cell Therapeutics warns cash is running low

Biotechnology company Cell Therapeutics said Friday in a regulatory filing that it has "an immediate need to raise additional capital in the next thirty days" to continue operations.

By Seattle Times staff

Biotechnology company Cell Therapeutics said Friday in a regulatory filing that without a capital infusion "we will have insufficient funds to continue operations through the end of the current fiscal quarter."

"We have an immediate need to raise additional capital in the next thirty days in order to meet our operation needs," the Seattle biotech said in a Securities and Exchange Commision filing.

The company said Friday that as of March 31, it had approximately $15.3 million in cash, securities and other current assets, compared to current liabilities of $47.9 million. Though it has not yet reported results for the quarter ended June 30, the company said that such assets "continue to be significantly less than our total current liabilities."

It gave no information on how it intends to raise additional funding.

Cell Therapeutics shares have fallen 80 percent this year, and closed Friday at 38 cents, down one cent or 2.6 percent.

More Business & Technology headlines...

E-mail article Print view Share: Digg Newsvine

More Business & Technology

Retail Report: Pacific Place not ready to see J.Jill go

Google CEO: New operating system changes the game

UPDATE - 04:21 PM
CEO vows better performance as GM exits bankruptcy

AIG to pay millions in bonuses to top execs — again

UPDATE - 04:30 PM
Regulators put Seattle Bank on tighter leash

Advertising

Video

Gen. David Petraeus: Iraq and Afghanistan Wars
Watch highlights of General David Petraeus discussing the Iraq and Afghanistan War at the Global Leadership Series sponsored by the World Affairs Council.